News stories about Halyard Health (NYSE:HYH) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Halyard Health earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.6046010362705 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

A number of research analysts have recently weighed in on HYH shares. TheStreet upgraded Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. Stifel Nicolaus restated a “buy” rating and set a $45.00 price objective on shares of Halyard Health in a research report on Thursday, September 21st. BidaskClub upgraded Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Deutsche Bank AG raised their price objective on Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Halyard Health has a consensus rating of “Buy” and a consensus target price of $42.25.

Halyard Health (NYSE:HYH) traded up 0.712% on Thursday, reaching $45.995. The company had a trading volume of 19,253 shares. Halyard Health has a 1-year low of $31.59 and a 1-year high of $46.63. The company’s 50-day moving average price is $44.97 and its 200 day moving average price is $40.19. The firm has a market capitalization of $2.15 billion, a P/E ratio of 44.226 and a beta of 1.75.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The company had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $399.16 million. During the same quarter in the prior year, the company earned $0.45 EPS. Halyard Health’s revenue was down .2% compared to the same quarter last year. On average, equities analysts forecast that Halyard Health will post $1.96 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Halyard Health (HYH) Earning Somewhat Positive Media Coverage, Report Shows” was first reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.